Profile data is unavailable for this security.
About the company
Organon & Co. is a global health care company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and established brands. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. The Company’s Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, respiratory, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. The Company operates six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom.
- Revenue in USD (TTM)6.35bn
- Net income in USD1.05bn
- Incorporated2021
- Employees10.00k
- LocationOrganon & Co30 Hudson Street, Fl 33JERSEY CITY 07302United StatesUSA
- Phone+1 (551) 430-6000
- Fax+1 (302) 655-5049
- Websitehttps://www.organon.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Twist Bioscience Corp | 277.49m | -192.14m | 2.87bn | 919.00 | -- | 5.12 | -- | 10.34 | -3.35 | -3.35 | 4.83 | 9.63 | 0.3565 | 4.87 | 7.04 | 301,943.40 | -24.68 | -30.50 | -27.12 | -33.84 | 38.29 | 36.02 | -69.24 | -113.33 | 5.06 | -- | 0.00 | -- | 20.41 | 57.33 | 6.08 | -- | 49.76 | -- |
| Corcept Therapeutics Incorporated | 523.53m | 118.02m | 3.38bn | 352.00 | 30.39 | 6.17 | 28.42 | 6.46 | 1.07 | 1.07 | 4.74 | 5.27 | 0.822 | 1.12 | 11.13 | 1,487,298.00 | 18.53 | 21.17 | 21.50 | 23.85 | 98.54 | 98.52 | 22.54 | 27.23 | 5.10 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
| Prestige Consumer Healthcare Inc | 1.13bn | 209.34m | 3.44bn | 570.00 | 16.50 | 2.07 | 14.32 | 3.05 | 4.17 | 4.17 | 22.43 | 33.22 | 0.3373 | 3.33 | 6.55 | 1,974,311.00 | 6.28 | 3.69 | 6.55 | 3.84 | 55.49 | 56.79 | 18.60 | 12.19 | 2.02 | 5.10 | 0.4052 | 0.00 | -0.21 | 2.89 | 354.34 | -- | -1.84 | -- |
| Perrigo Company PLC | 4.56bn | 700.00k | 3.50bn | 9.14k | 8,126.58 | 0.7468 | 9.92 | 0.7684 | 0.0032 | -0.0585 | 33.33 | 34.39 | 0.4219 | 2.54 | 5.78 | 498,457.30 | 0.0065 | -0.1148 | 0.0074 | -0.1315 | 35.65 | 35.28 | 0.0154 | -0.2985 | 1.08 | 1.26 | 0.4645 | -- | 4.58 | -0.3238 | 96.64 | -- | -5.95 | 7.52 |
| Axsome Therapeutics Inc | 251.02m | -296.38m | 3.82bn | 545.00 | -- | 26.53 | -- | 15.23 | -6.38 | -6.38 | 5.41 | 3.03 | 0.537 | 2.11 | 3.43 | 460,592.70 | -63.40 | -64.55 | -85.88 | -82.23 | 90.12 | -- | -118.07 | -227.05 | 3.09 | -55.54 | 0.556 | -- | 440.80 | -- | -27.84 | -- | 77.86 | -- |
| Avidity Biosciences Inc | 10.87m | -228.68m | 4.34bn | 253.00 | -- | 4.70 | -- | 398.90 | -2.95 | -2.95 | 0.1408 | 8.69 | 0.0139 | -- | -- | 42,964.43 | -29.22 | -31.61 | -31.71 | -34.45 | -- | -- | -2,103.78 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
| Apellis Pharmaceuticals Inc | 524.07m | -417.27m | 4.66bn | 702.00 | -- | 17.44 | -- | 8.88 | -3.46 | -3.46 | 4.33 | 2.20 | 0.5788 | 0.5747 | 3.50 | 746,538.40 | -46.09 | -73.88 | -57.28 | -90.03 | 86.47 | -- | -79.62 | -326.49 | 3.02 | -39.71 | 0.6087 | -- | 425.83 | -- | 18.94 | -- | -- | -- |
| BridgeBio Pharma Inc | 218.60m | -538.26m | 4.74bn | 550.00 | -- | -- | -- | 21.68 | -3.23 | -3.23 | 1.29 | -5.61 | 0.2964 | -- | -- | 397,449.10 | -74.13 | -72.44 | -90.19 | -89.72 | 98.91 | 94.41 | -250.09 | -1,225.66 | -- | -11.48 | 2.53 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
| Organon & Co | 6.35bn | 1.05bn | 5.32bn | 10.00k | 5.08 | 110.33 | 4.12 | 0.8387 | 4.08 | 4.08 | 24.71 | 0.1876 | 0.5603 | 2.18 | 4.24 | 634,700.00 | 9.24 | 16.53 | 11.79 | 20.97 | 59.04 | 65.12 | 16.50 | 26.79 | 1.15 | 2.36 | 0.9945 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.72 | -- |
| Jazz Pharmaceuticals PLC | 3.84bn | 330.79m | 6.73bn | 2.80k | 22.02 | 1.82 | 6.88 | 1.75 | 4.85 | 4.85 | 55.49 | 58.65 | 0.3436 | 0.6428 | 5.78 | 1,372,634.00 | 2.99 | 1.48 | 3.36 | 1.62 | 89.53 | 88.79 | 8.69 | 4.26 | 1.90 | 2.00 | 0.607 | 0.00 | 4.78 | 15.19 | 285.14 | -1.49 | -20.04 | -- |
| Elanco Animal Health Inc | 4.37bn | -1.30bn | 7.13bn | 9.30k | -- | 1.18 | -- | 1.63 | -2.64 | -2.64 | 8.84 | 12.26 | 0.2931 | 1.21 | 4.28 | 469,354.80 | -8.74 | -3.27 | -9.65 | -3.65 | 55.28 | 54.28 | -29.83 | -11.53 | 1.96 | 0.853 | 0.4877 | -- | 0.136 | 7.57 | -1,478.21 | -- | 2.74 | -- |
| Intra-Cellular Therapies Inc | 513.93m | -110.87m | 7.23bn | 610.00 | -- | 11.14 | -- | 14.07 | -1.15 | -1.15 | 5.34 | 6.15 | 0.6996 | 1.67 | 4.83 | 842,508.20 | -15.09 | -38.27 | -17.67 | -42.77 | 92.82 | -- | -21.57 | -128.42 | 5.00 | -- | 0.00 | -- | 85.51 | -- | 45.49 | -- | -7.22 | -- |
| Roivant Sciences Ltd | 124.80m | 4.35bn | 7.81bn | 845.00 | 2.09 | 1.43 | 1.84 | 62.57 | 5.07 | 5.07 | 0.1571 | 7.40 | 0.026 | 0.8187 | 2.97 | 147,686.40 | 88.04 | -- | 103.92 | -- | 87.53 | -- | 3,390.53 | -- | 25.10 | -- | 0.0642 | -- | 103.65 | -- | 487.06 | -- | -- | -- |
Data as of Jun 28 2024. Currency figures normalised to Organon & Co's reporting currency: US Dollar USD
42.56%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 30.85m | 12.00% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 30.28m | 11.78% |
| Massachusetts Financial Services Co.as of 31 Mar 2024 | 10.15m | 3.95% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 9.30m | 3.61% |
| Citadel Advisors LLCas of 31 Mar 2024 | 5.57m | 2.16% |
| Slate Path Capital LPas of 31 Mar 2024 | 5.15m | 2.00% |
| Sound Shore Management, Inc.as of 31 Mar 2024 | 5.02m | 1.95% |
| Nordea Investment Management ABas of 30 Apr 2024 | 4.68m | 1.82% |
| LSV Asset Managementas of 31 Mar 2024 | 4.49m | 1.75% |
| Nordea Investment Management AB (Denmark)as of 31 Mar 2024 | 3.97m | 1.54% |
More ▼
Data from 31 Mar 2024 - 30 Apr 2024Source: FactSet Research Systems Inc.
